Mumbai: With the launch of the Bulk Drug Manufacturers Association of India (BDMAI)’s e-marketing portal, Indian pharma companies can now promote exclusively Indian APIs, intermediates, pellets, impurities, contract development and manufacturing organization (CDMO)/contract research and manufacturing services (CRAM) services in domestic and global markets, according to industry experts.
Designed as a one-stop digital marketplace, this platform aims to strengthen industry visibility, enhance connectivity, and support the global outreach of Indian bulk drug manufacturers.
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has also urged its member companies to register as BUYER, start search and send enquiries for selected products/manufacturers. The portal offers exclusive no cost to the buyers of APIs.
“It also has a Vendor Management facility which can help in creating a comprehensive and integrated ecosystem for the industry as most of our members are into manufacturing of finished formulations, this portal www.bdmaiem.inhelps in souring of APIs,” informs Pharmexcil director general (DG) K. Raja Bhanu.
The portal allows users to search by product name, company name, CAS number, or HS code, making it simple and efficient to find specific products or manufacturers. It also features an integrated enquiry system, allowing users to send direct enquiries to selected companies through the app itself.
BDMAI brings together the leading manufacturers of APIs, intermediates, pallets, impurities, CDMOs and other related service providers from across the country. Established in 1991 with the aim of promoting the growth, competitiveness, and global standing of India’s bulk drug industry, the Association serves as a unified platform for collaboration, representation, and advancement. It works closely with Central and state governments, regulatory authorities, and industry stakeholders to address common challenges and advocate for policies that strengthen the bulk drug manufacturing ecosystem.
Beyond policy advocacy, the Association actively engages in knowledge sharing, technical seminars, training programs, and industry–academia collaborations to support continuous improvement in quality, compliance, innovation, and sustainability.
%20In%20Drug%20Development){kind=link}